Stocktoria
X4 Pharmaceuticals, Inc XFOR
X4 Pharmaceuticals, Inc statistics & valuation
Market cap$381.1M
P / S10.9×
P / B2.0×
Net margin-225.6%
Return on equity-42.5%
Net cash$142.0M
Enterprise value USD$239.0M
Earnings yield EBIT/EV-36.4%
Return on capital-32.8%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -247.4% | -1400.0% | — | — | — | -1995.8% | — | — | — |
| Net margin | -225.6% | -1440.4% | — | — | — | -2071.0% | — | — | — |
| FCF margin | — | -5047.2% | — | — | — | — | — | — | — |
| Return on assets | -27.3% | -25.6% | -68.7% | -60.3% | -75.7% | -50.6% | -32.9% | -334.7% | -27.1% |
| Return on equity | -42.5% | -169.1% | -198.0% | -126.8% | -137.7% | -85.3% | -40.9% | 43.2% | 49.4% |
| Debt / equity | 0.40× | 3.39× | 1.08× | 0.44× | 0.51× | 0.46× | 0.15× | -0.13× | — |
| Current ratio | 10.16 | 3.41 | 5.34 | 5.76 | 6.27 | 6.97 | 13.68 | 1.18 | 7.45 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.